Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Michael J. Wright

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3353-6664; OpenAlex author ID A5101489376. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 11

  1. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. Co-author DOI 10.1067/j.cpradiol.2024.03.001↗
  2. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. First author DOI 10.1002/jhbp.1303↗
  3. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.1007/s00268-021-06410-y↗
  4. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.21.00404↗
  5. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Impli… Co-author DOI 10.1007/s11605-021-05078-y↗
  6. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  7. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.jamcollsurg.2020.11.018↗
  8. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… First author DOI 10.1245/s10434-020-09201-2↗
  9. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04311-z↗
  10. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  11. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. First author DOI 10.1007/s11605-018-3966-8↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 11 shared papers, 2019–2024 · strength 1.30
  2. Ammar A. Javed · 10 shared papers, 2019–2024 · strength 1.17
  3. Ding Ding · 10 shared papers, 2019–2023 · strength 1.10
  4. Christopher Lee Wolfgang · 9 shared papers, 2019–2024 · strength 1.06
  5. Richard Andrew Burkhart · 8 shared papers, 2019–2023 · strength 0.88
  6. Matthew John Weiss · 7 shared papers, 2019–2024 · strength 0.84
  7. William R. Burns · 7 shared papers, 2021–2023 · strength 0.83
  8. Jun Yu · 4 shared papers, 2021–2023 · strength 0.45
  9. Amol Kumar Narang · 4 shared papers, 2019–2022 · strength 0.39
  10. Kelly J. Lafaro · 3 shared papers, 2021–2022 · strength 0.38
  11. Elliot K. Fishman · 3 shared papers, 2021–2024 · strength 0.38
  12. Ralph H. Hruban MD · 3 shared papers, 2021–2023 · strength 0.37
  13. Lei Zheng · 3 shared papers, 2019–2022 · strength 0.26
  14. Daniel A. Laheru · 3 shared papers, 2019–2022 · strength 0.26
  15. Ryan K. Schmocker · 2 shared papers, 2021 · strength 0.25
  16. Christopher L. Wolfgang · 2 shared papers, 2021–2023 · strength 0.24
  17. Richard A. Burkhart · 2 shared papers, 2020–2021 · strength 0.23
  18. Taha Muneer Ahmed · 1 shared paper, 2024 · strength 0.20
  19. Mohammad Yasrab · 1 shared paper, 2024 · strength 0.20
  20. Satomi Kawamoto · 1 shared paper, 2024 · strength 0.20
  21. Linda Chi Hang Chu · 1 shared paper, 2024 · strength 0.20
  22. Robert A. Anders · 2 shared papers, 2021–2022 · strength 0.18
  23. Dung Thi Le · 2 shared papers, 2021–2022 · strength 0.18
  24. Ana De Jesus‐Acosta · 2 shared papers, 2021–2022 · strength 0.18
  25. Vikesh K. Singh · 2 shared papers, 2021–2022 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.